Skip to main content
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Applications for the 2023/24 High Cost Device List are open in England

In March 2022, NHS England opened a call for applications to the High Cost Device List (HCDL) changes for the 2023/24 National Tariff Payment System.

Some high cost devices (and drugs) are excluded from calculating unit and national prices under the National Tariff Payment System. HCDL items that are funded nationally by NHS England are paid in addition to the price of the related service. Those HCDL items, funded locally by Clinical Commissioning Groups, are integrated into the fixed component of the aligned payment and incentive approach (current payment model in England).

To nominate a drug or device to be added or removed from the HCDL for 2023/24, the application form should be filled in and sent via email ( by May 31, 2022. Nominations submitted after this date may be considered for a future tariff.

See the full details here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). First EU issues of both newsletters are available for download free-of-charge.

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).